According to filings with the U.S. Securities and Exchange Commission, NKA Bio is raising $2,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Susan Hibbs played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About NKA Bio
NKA Bio was founded with a mission to improve trauma care by solving shock. The company is focused on its primary product NKA01 for Trauma Resuscitation. The early-stage pipeline in development includes programs for septic shock, acute lung injury, and heart attack resuscitation. Every day, medical professionals in the US run out of time and patients bleed to death. On average: 148,000 people die every year from hemorrhage-related injuries. Annually, 211,530 hemorrhage-related patients admitted to trauma center ICUs. In the US, most hemorrhage-related trauma patients spend 3-4 days in the ICU. Reducing ICU care would save a per-patient average of $4,300 per day. A drug to resuscitate and stabilize patients in shock, would create an opportunity to save lives and reduce trauma care costs.

To learn more about NKA Bio, visit http://www.nkabio.com/

Contact:
Susan Hibbs, Chief Executive Officer
443-465-7702

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.